PQ203 for advanced solid tumors like triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This early-phase trial tests a new drug called PQ203 for people with advanced solid tumors, including triple-negative breast cancer, that have stopped responding to standard treatments. It helps doctors learn whether the drug is safe and how it affects tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have a type of advanced solid tumor cancer (including triple-negative breast cancer) that has progressed or is not eligible for standard treatments.
- Your cancer has at least one tumor that can be measured on a scan (CT or MRI).
- You are in generally good health (able to do light work or be up and about) and your major organs (bone marrow, liver, kidneys) are working well enough based on blood tests.
- You have not had a stroke or certain eye, lung, or nerve problems in the past, and you are not pregnant or nursing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, QLC5513, given alone or with another drug called QL1706, for people with advanced or metastatic triple-negative breast cancer (TNBC) that has worsened after at least one previous treatment. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
This trial tests a combination of an immunotherapy (camrelizumab), an anti-fibrotic drug (pirfenidone), and standard chemotherapy for people with advanced triple-negative breast cancer that has not gotten worse after initial treatment. The goal is to see if this mix works better than chemo alone.
This trial tests a new immunotherapy drug (QL1706) combined with a short course of common chemotherapy (anthracyclines or taxanes) for people with early-stage triple-negative breast cancer. The goal is to see if this combination is safe and helps shrink the tumor before surgery.
This trial tests if adding a new immunotherapy drug (QL1706) to standard chemotherapy works better than chemotherapy alone for triple-negative breast cancer that has returned or spread. This is for people who have already tried 1 or 2 other treatments.
This trial tests a combination of an immunotherapy drug (QL1706) plus chemotherapy given before surgery to shrink early high-risk triple-negative breast cancer. The goal is to see if this treatment can improve the chance of a complete response (no cancer left at surgery).
Hear when a new Triple Negative Breast Cancer (TNBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.